{
    "clinical_study": {
        "@rank": "33281", 
        "arm_group": [
            {
                "arm_group_label": "Asenapine 5-20 mg daily", 
                "arm_group_type": "Experimental", 
                "description": "Asenapine will be started at 5 mg BID. The asenapine dose can be increased to 15 mg daily and then to 20 mg daily, or reduced to 5 mg daily, depending on therapeutic response and tolerability"
            }, 
            {
                "arm_group_label": "Placebo 1-4 tablets daily", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Matched, blinded placebo tablets will be administered at doses from 1-4 tablets daily depending on therapeutic response and tolerability"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a 6-week comparison of asenapine versus placebo as an add-on to ongoing\n      antidepressant treatment in patients with major depression who have not had a complete\n      therapeutic response to treatment with the antidepressant alone.\n\n      The investigators hypothesize that added asenapine will produce greater reductions in\n      depression than will added placebo."
        }, 
        "brief_title": "Antidepressant Plus Asenapine Versus Antidepressant Plus Placebo for Depression", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Major Depressive Disorder Without Psychotic Features", 
        "condition_browse": {
            "mesh_term": [
                "Depression", 
                "Depressive Disorder", 
                "Mental Disorders", 
                "Psychotic Disorders", 
                "Depressive Disorder, Major"
            ]
        }, 
        "detailed_description": {
            "textblock": "The investigators will undertake a 6-week, double-blind, randomized, parallel-group,\n      placebo-controlled trial of adjunctive asenapine in 130 patients with MDD without psychosis\n      who have had an incomplete therapeutic response to treatment with an antidepressant\n      medication alone."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        -130 male or female patients, 18-65 years of age, with:\n\n          1. DSM-IV diagnosis of MDD without psychosis (single episode or recurrent) confirmed by\n             the Mini-International Neuro-psychiatric Interview (MINI)\n\n          2. MADRS total score >  20, and item 1 (Apparent Sadness) score > 2 at enrollment and\n             randomization\n\n          3. Inadequate therapeutic response during their current depressive episode; an\n             inadequate therapeutic response will be defined as continued depressive\n             psychopathology (see criterion 2) following > six weeks of therapy at adequate doses\n             (according to the US label) of any non-tricyclic, non-MAOI antidepressant medication\n\n        Exclusion Criteria:\n\n          1. Additional DSM-IV Axis I diagnoses other than Generalized Anxiety Disorder, Panic\n             Disorder with or without Agoraphobia, or Social Phobia within 6 months prior to\n             enrollment\n\n          2. DSM-IV Axis II diagnoses that significantly impact the current psychiatric status\n\n          3. Current MDD episode lasting > 12 months\n\n          4. Electroconvulsive therapy within the preceding 6 months\n\n          5. Substance or alcohol dependence, as defined by DSM-IV criteria, within 6 months prior\n             to enrollment\n\n          6. Unstable medical illness, epilepsy, traumatic brain injury, Parkinson disease, or\n             dementia (MMSE <24)\n\n          7. Risk of suicide as defined by MADRS item 10 score > 4\n\n          8. Prior failure to respond to asenapine\n\n          9. Pregnancy or failure to use an acceptable form of birth control. Pregnancy as\n             determined by serum pregnancy test at baseline\n\n         10. Hepatic impairment and history of low WBC, by medical history and interview."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "130", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01670019", 
            "org_study_id": "Pro00037462"
        }, 
        "intervention": [
            {
                "arm_group_label": "Asenapine 5-20 mg daily", 
                "description": "5 mg QHS, or 5 mg BID, or 5 mg QAM and 10 mg QHS, or 10 mg BID", 
                "intervention_name": "Asenapine 5-20 mg daily", 
                "intervention_type": "Drug", 
                "other_name": "SAPHRIS"
            }, 
            {
                "arm_group_label": "Placebo 1-4 tablets daily", 
                "description": "One placebo tablet QHS, or one placebo tablet BID, or one placebo tablet QAM and two placebo tablets QHS, or two placebo tablets BID", 
                "intervention_name": "Placebo 1-4 tablets daily", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antidepressive Agents", 
                "Asenapine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Depression", 
            "Antidepressant", 
            "Antipsychotic"
        ], 
        "lastchanged_date": "August 8, 2013", 
        "location": [
            {
                "contact": {
                    "email": "ssebasti@georgiahealth.edu", 
                    "last_name": "Simon C Sebastion, MD", 
                    "phone": "706-721-7178"
                }, 
                "contact_backup": {
                    "email": "afoster@georgiahealth.edu", 
                    "last_name": "Adriana Foster, MD", 
                    "phone": "706-721-7488"
                }, 
                "facility": {
                    "address": {
                        "city": "Augusta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30912"
                    }, 
                    "name": "Georgia Health Sciences University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "john.beyer@duke.edu", 
                    "last_name": "John L Beyer, MD", 
                    "phone": "919-668-0209"
                }, 
                "contact_backup": {
                    "email": "nabila.lateef@duke.edu", 
                    "last_name": "Nabila Lateef, RN", 
                    "phone": "919-684-9701"
                }, 
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Duke University Medical Center"
                }, 
                "investigator": {
                    "last_name": "John L Beyer, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "rmillet@carolinabehavioralcare.com", 
                    "last_name": "Robert A Millet, MD", 
                    "phone": "919-972-7700"
                }, 
                "contact_backup": {
                    "email": "elueth@carolinabehavioralcare.com", 
                    "last_name": "Edward S Lueth, MSW", 
                    "phone": "919-972-7700"
                }, 
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27704"
                    }, 
                    "name": "Carolina Behavioral Care"
                }, 
                "investigator": {
                    "last_name": "Robert A Miller, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "johnn@ecu.edu", 
                    "last_name": "Nadyah J John, MD", 
                    "phone": "252-744-2673"
                }, 
                "contact_backup": {
                    "email": "blochri@ecu.edu", 
                    "last_name": "Richard M Bloch, PhD", 
                    "phone": "252-744-3324"
                }, 
                "facility": {
                    "address": {
                        "city": "Greenville", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27834"
                    }, 
                    "name": "Brody School of Medicine at East Carolina University"
                }, 
                "investigator": {
                    "last_name": "Nadyah J John, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "joy.w.smith@dhhs.nc.gov", 
                    "last_name": "Joy W Smith, RN", 
                    "phone": "919-733-5229"
                }, 
                "contact_backup": {
                    "email": "lars_jarskog@med.unc.edu", 
                    "last_name": "Lars F Jarskog, MD", 
                    "phone": "919-715-9157"
                }, 
                "facility": {
                    "address": {
                        "city": "Raleigh", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27603"
                    }, 
                    "name": "North Carolina Psychiatric Research Center"
                }, 
                "investigator": {
                    "last_name": "Lars F Jarskog, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Blinded, Comparison of Asenapine and Placebo as Adjunctive Treatment in Patients With Non-Psychotic Major Depressive Disorder Incompletely Responsive to Antidepressant Monotherapy", 
        "overall_contact": {
            "email": "beyer001@mc.duke.edu", 
            "last_name": "John Beyer, MD", 
            "phone": "919-668-0209"
        }, 
        "overall_contact_backup": {
            "email": "WILSO066@MC.DUKE.EDU", 
            "last_name": "William H Wilson, PH.D.", 
            "phone": "919-575-7360"
        }, 
        "overall_official": {
            "affiliation": "Duke University", 
            "last_name": "John Beyer, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The Montgomery Asberg Depression Rating Scale (MADRS) is used by clinicians to assess the severity of depression among patients with a diagnosis of depression. It is designed to be sensitive to change resulting from antidepressant therapy.\n10 items", 
            "measure": "Change in MADRS total score", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01670019"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The percentage of patients still taking their assigned treatment (asenapine or placebo) at the end of 6 weeks", 
                "measure": "Study completion rate", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "Response will be defined as a > 50% reduction from baseline in MADRS total score. Remission will be defined as a MADRS total score < 7.  Sustained remission will be defined as at least two consecutive post-randomization assessments (weeks 2, 4, and 6) during which minimal depressive psychopathology (MADRS < 7) is present.", 
                "measure": "Rates of response, remission, and sustained remission", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }
        ], 
        "source": "Duke University", 
        "sponsors": {
            "collaborator": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Duke University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}